The investigative agent mavacamten may be safe and effective in patients with non-obstructive hypertrophic cardiomyopathy (HCM), researchers reported. In the primary safety endpoint of the MAVERICK ...
Cytokinetics (NASDAQ:CYTK) used its presentation at Citi’s Life Sciences Conference to highlight the recent U.S. approval of ...
SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...
ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
BOSTON--(BUSINESS WIRE)--Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart ...
"The findings of this trial help us understand that obstructive HCM and nonobstructive HCM are two unique diseases," said trial investigator Dr Milind Desai. Topline results were announced from a ...
Many drugs available and in development work by targeting proteins, an approach that comes with limitations. For one, proteins are not the root cause of disease, said Samir Ounzain, co-founder and CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results